Reportable Segment Information

12 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Reportable Segment Information

12.  Reportable Segment Information

Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. We operate two reportable segments:

• Medical Device: Surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices; drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and structural heart, among others; and the design, development and manufacture of interventional medical devices, primarily balloons and catheters, including drug-coated balloons, for peripheral arterial disease treatment and other applications; and

• In Vitro Diagnostics: Design, development and manufacture of component products and technologies for diagnostic immunoassay as well as molecular test and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

Segment revenue, operating (loss) income, and depreciation and amortization were as follows:

	Fiscal Year
(In thousands)	2020			2019			2018
Revenue:
Medical Device	$	71,401		$	78,353		$	60,513
In Vitro Diagnostics		23,463			21,724			20,823
Total revenue	$	94,864		$	100,077		$	81,336
Operating (loss) income:
Medical Device	$	(3,246	)	$	4,794		$	(8,478	)
In Vitro Diagnostics		11,771			10,620			8,619
Total segment operating (loss) income		8,525			15,414			141
Corporate		(9,776	)		(8,945	)		(8,940	)
Total operating (loss) income	$	(1,251	)	$	6,469		$	(8,799	)
Depreciation and amortization:
Medical Device	$	6,223		$	5,811		$	5,376
In Vitro Diagnostics		483			464			394
Corporate		557			1,037			661
Total depreciation and amortization	$	7,263		$	7,312		$	6,431

The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.

Revenue from customers that equaled or exceeded 10% of total revenue was as follows:

	Fiscal Year
	2020			2019			2018
Abbott		19	%		19	%		11	%
Medtronic		14	%		14	%		16	%

The revenue from the customers listed is derived from two primary sources: licensing and product sales (primarily in the Medical Device segment).

Revenue by geographic region was as follows:

	Fiscal Year
	2020			2019			2018
Domestic		78	%		81	%		79	%
Foreign		22	%		19	%		21	%

Long-lived assets by country, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, were as follows:

	September 30,
(In thousands)	2020		2019
U.S.	$	25,273	$	24,450
Ireland		18,113		19,524